Not “doing the same thing over and over again”

Daniel F. Hanley; Wendy C. Ziai; Issam A. Awad

doi:10.17925/usn.2018.14.1.29

Not “doing the same thing over and over again”

Daniel F. Hanley, Wendy C. Ziai, Issam A. Awad

School of Medicine

Research output: Contribution to journal › Editorial › peer-review

Abstract

Intracerebral hemorrhage (ICH) with intraventricular extension is a devastating disease occurring in 40% of patients with spontaneous ICH. Although the CLEAR III trial (NCT00784134) demonstrated mortality reduction with intraventricular alteplase (versus saline), lessons learned warrant a therapeutic trial focusing on disease severity and treatment endpoints that support a high likelihood of improvement. We must answer questions of maximizing therapy intensity in large intraventricular hemorrhage (IVH) to promote good neurologic outcomes if we are committed to treating ICH and the full spectrum of stroke severity.

Original language	English (US)
Pages (from-to)	29-30
Number of pages	2
Journal	European Neurological Review
Volume	14
Issue number	1
DOIs	https://doi.org/10.17925/usn.2018.14.1.29
State	Published - Mar 1 2018

Keywords

Alteplase
CLEAR III
Extra-ventricular drain (EVD)
Intracerebral hemorrhage (ICH)
Intraventricular hemorrhage (IVH)
Stroke

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.17925/usn.2018.14.1.29

Cite this

@article{a3a18adf9ae94aee9e5e378868f46811,

title = "Not “doing the same thing over and over again”",

abstract = "Intracerebral hemorrhage (ICH) with intraventricular extension is a devastating disease occurring in 40% of patients with spontaneous ICH. Although the CLEAR III trial (NCT00784134) demonstrated mortality reduction with intraventricular alteplase (versus saline), lessons learned warrant a therapeutic trial focusing on disease severity and treatment endpoints that support a high likelihood of improvement. We must answer questions of maximizing therapy intensity in large intraventricular hemorrhage (IVH) to promote good neurologic outcomes if we are committed to treating ICH and the full spectrum of stroke severity.",

keywords = "Alteplase, CLEAR III, Extra-ventricular drain (EVD), Intracerebral hemorrhage (ICH), Intraventricular hemorrhage (IVH), Stroke",

author = "Hanley, {Daniel F.} and Ziai, {Wendy C.} and Awad, {Issam A.}",

note = "Funding Information: Disclosure: Daniel F Hanley, Wendy C Ziai and Issam A Awad are supported by research grant #5U01NS062851 from the US National Institutes of Health National Institute of Neurological Disorders and Stroke (NIH/NINDS). Daniel F Hanley and Issam A Awad have both received compensation for legal expert opinions. Daniel F Hanley is also supported by NIH/NINDS research grant #U24TR001609, holds IND #8523 for the intracerebral use of rt-PA, and is a member of the journal's editorial board. Publisher Copyright: {\textcopyright} The Authors 2018.",

year = "2018",

month = mar,

day = "1",

doi = "10.17925/usn.2018.14.1.29",

language = "English (US)",

volume = "14",

pages = "29--30",

journal = "European Neurological Review",

issn = "1758-3837",

publisher = "Touch Briefings",

number = "1",

}

TY - JOUR

T1 - Not “doing the same thing over and over again”

AU - Hanley, Daniel F.

AU - Ziai, Wendy C.

AU - Awad, Issam A.

N1 - Funding Information: Disclosure: Daniel F Hanley, Wendy C Ziai and Issam A Awad are supported by research grant #5U01NS062851 from the US National Institutes of Health National Institute of Neurological Disorders and Stroke (NIH/NINDS). Daniel F Hanley and Issam A Awad have both received compensation for legal expert opinions. Daniel F Hanley is also supported by NIH/NINDS research grant #U24TR001609, holds IND #8523 for the intracerebral use of rt-PA, and is a member of the journal's editorial board. Publisher Copyright: © The Authors 2018.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Intracerebral hemorrhage (ICH) with intraventricular extension is a devastating disease occurring in 40% of patients with spontaneous ICH. Although the CLEAR III trial (NCT00784134) demonstrated mortality reduction with intraventricular alteplase (versus saline), lessons learned warrant a therapeutic trial focusing on disease severity and treatment endpoints that support a high likelihood of improvement. We must answer questions of maximizing therapy intensity in large intraventricular hemorrhage (IVH) to promote good neurologic outcomes if we are committed to treating ICH and the full spectrum of stroke severity.

AB - Intracerebral hemorrhage (ICH) with intraventricular extension is a devastating disease occurring in 40% of patients with spontaneous ICH. Although the CLEAR III trial (NCT00784134) demonstrated mortality reduction with intraventricular alteplase (versus saline), lessons learned warrant a therapeutic trial focusing on disease severity and treatment endpoints that support a high likelihood of improvement. We must answer questions of maximizing therapy intensity in large intraventricular hemorrhage (IVH) to promote good neurologic outcomes if we are committed to treating ICH and the full spectrum of stroke severity.

KW - Alteplase

KW - CLEAR III

KW - Extra-ventricular drain (EVD)

KW - Intracerebral hemorrhage (ICH)

KW - Intraventricular hemorrhage (IVH)

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85045146907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045146907&partnerID=8YFLogxK

U2 - 10.17925/usn.2018.14.1.29

DO - 10.17925/usn.2018.14.1.29

M3 - Editorial

AN - SCOPUS:85045146907

SN - 1758-3837

VL - 14

SP - 29

EP - 30

JO - European Neurological Review

JF - European Neurological Review

IS - 1

ER -

Not “doing the same thing over and over again”

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this